ABSTRACT - 603831 The disclosure relates to triazol-dihydropyrazino[2,3-h ]pyrazin-2(1H)-one derivative compounds having formula (II) or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, or tautomer thereof, wherein: R1 is substituted or unsubstituted aryl R2 is H, substituted or unsubstituted C1- 8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl R3 is H, or a substituted or unsubstituted C1- 8 alkyl provided the compound of formula (II) is not 7-(4-hydroxyphenyl)-1-(3- methoxybenzyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one. These compounds are suitable for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
